• Target：
• CD4

• Fields：
• >>Viral life cycle - HIV-1;>>Cytokine-cytokine receptor interaction;>>Cell adhesion molecules;>>Antigen processing and presentation;>>Hematopoietic cell lineage;>>Th1 and Th2 cell differentiation;>>Th17 cell differentiation;>>T cell receptor signaling pathway;>>Yersinia infection;>>Human T-cell leukemia virus 1 infection;>>Human immunodeficiency virus 1 infection;>>PD-L1 expression and PD-1 checkpoint pathway in cancer;>>Primary immunodeficiency

• Gene Name：
• CD4

• Protein Name：
• T-cell surface glycoprotein CD4

• Human Gene Id：
• 920

• Human Swiss Prot No：
• P01730

• Mouse Gene Id：
• 12504

• Mouse Swiss Prot No：
• P06332

• Rat Gene Id：
• 24932

• Rat Swiss Prot No：
• P05540

• Immunogen：
• Synthetic Peptide of CD4

• Specificity：
• The antibody detects endogenous CD4 proteins.

• Formulation：
• PBS, pH 7.4, containing 0.5%BSA, 0.02% sodium azide as Preservative and 50% Glycerol.

• Source：
• Monoclonal, Mouse

• Dilution：
• IHC 1:200

• Purification：
• The antibody was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen.

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• CD4;T-cell surface glycoprotein CD4;T-cell surface antigen T4/Leu-3;CD4

• Molecular Weight(Da)：
• 51kD

• Background：
• This gene encodes a membrane glycoprotein of T lymphocytes that interacts with major histocompatibility complex class II antigenes and is also a receptor for the human immunodeficiency virus. This gene is expressed not only in T lymphocytes, but also in B cells, macrophages, and granulocytes. It is also expressed in specific regions of the brain. The protein functions to initiate or augment the early phase of T-cell activation, and may function as an important mediator of indirect neuronal damage in infectious and immune-mediated diseases of the central nervous system. Multiple alternatively spliced transcript variants encoding different isoforms have been identified in this gene. [provided by RefSeq, Aug 2010],

• Function：
• function:Accessory protein for MHC class-II antigen/T-cell receptor interaction. May regulate T-cell activation. Induces the aggregation of lipid rafts.,miscellaneous:Primary receptor for HIV-1.,online information:CD4 entry,PTM:Palmitoylation and association with LCK contribute to the enrichment of CD4 in lipid rafts.,similarity:Contains 1 Ig-like V-type (immunoglobulin-like) domain.,similarity:Contains 3 Ig-like C2-type (immunoglobulin-like) domains.,subcellular location:Localizes to lipid rafts. Removed from plasma membrane by HIV-1 Nef protein that increases clathrin-dependent endocytosis of this antigen to target it to lysosomal degradation. Cell surface expression is also down-modulated by HIV-1 Envelope polyprotein gp160 that interacts with, and sequesters CD4 in the endoplasmic reticulum.,subunit:Associates with LCK. Binds to HIV-1 gp120 and to P4HB/PDI and upon HIV-1 binding to t

• Subcellular Location：
• Cell membrane ; Single-pass type I membrane protein . Localizes to lipid rafts (PubMed:12517957, PubMed:9168119). Removed from plasma membrane by HIV-1 Nef protein that increases clathrin-dependent endocytosis of this antigen to target it to lysosomal degradation. Cell surface expression is also down-modulated by HIV-1 Envelope polyprotein gp160 that interacts with, and sequesters CD4 in the endoplasmic reticulum.

• Expression：
• Highly expressed in T-helper cells. The presence of CD4 is a hallmark of T-helper cells which are specialized in the activation and growth of cytotoxic T-cells, regulation of B cells, or activation of phagocytes. CD4 is also present in other immune cells such as macrophages, dendritic cells or NK cells.

Continuous ZnO nanoparticle exposure induces melanoma-like skin lesions in epidermal barrier dysfunction model mice through anti-apoptotic effects mediated by the oxidative stress–activated NF-κB pathway J Nanobiotechnol. 2022 Dec;20(1):1-23. IHC Mouse,Human 1:300 skin tissue

Preparation of an acellular spinal cord scaffold to improve its biological properties. Molecular Medicine Reports 2019 Aug 01 IHC Rat 1:200 Wounds

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs